The Healthcare Distribution Alliance (HDA) released the following statement following the organization’s testimony before the Senate Judiciary Committee on “Tackling the Opioid Crisis: A Whole-of-Government Approach.”
A new analysis published by the HDA Research Foundation indicates that oncology drugs, autoimmune and HIV therapeutics fueled specialty pharmaceutical segment growth in 2018. The 2019 Specialty Pharmaceutical Distribution: Facts, Figures and Trends indicates that oncology therapeutics account for most specialty distributor sales at 48.4 percent.
In 2018, sales through pharmaceutical distributors increased by 6.7 percent, reaching $492.54 billion, according to a new report by the HDA Research Foundation. The 90th Edition HDA Factbook: The Facts, Figures and Trends in Healthcare (2019–2020) also notes that chain drug stores were the largest customer base for pharmaceutical wholesalers — accounting for 44.6 percent of all sales, a slight increase from 2017. Distributor margins, however, continued a four-year slide, though they showed increases in efficiency.
In response to the Drug Enforcement Administration’s (DEA) proposed regulations related to the review and monitoring of annual production quotas, the Healthcare Distribution Alliance (HDA) released the following statement.
The Healthcare Distribution Alliance (HDA) announced that Greg Drew, RPh, President of Value Drug Company, and Robert Mauch, PhD, PharmD, EVP and Group President of AmerisourceBergen Corporation, were recently elected to second terms as Chairman and Vice Chairman of the HDA Board of Directors.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
